José Garcia-Sáenz

40PUBLICATIONS
537CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsDevelopmental genetics (incl. sex determination)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Apr 06, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Komal Jhaveri, Lisa D Eli, Sara A Hurvitz

|Dec 12, 2025
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

|Nov 03, 2025
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025).

Jose Angel Garcia-Saenz, Isabel Blancas Lopez-Barajas, Isabel Echavarria

|Sep 10, 2025
A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer.

Luis Manso, Rodrigo Sánchez-Bayona, Juan Antonio Guerra

|Jun 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.

Federico Rojo, Clive R Taylor, Carlos Barrios

|Jun 13, 2025
Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation.

Laura Lema, José Manuel Pérez-García, Salvador Blanch

Pageof 7

Frequent Collaborators

12 joint publications

Heli Nevanlinna

12 joint publications

Paul D P Pharoah

12 joint publications

Marjanka K Schmidt

12 joint publications

Emmanouil Saloustros